India has embarked on a third and final phase of clinical vaccine trials against the coronavirus Covaxin. The drug was developed by Bharat Biotech in collaboration with the Indian Council for Medical Research (ICMR), according to the TV channel NDTV …
Among the volunteers was the Vice-Chancellor of the Aligarh Muslim University (AMU) Tariq Mansur .
The vaccine is planned to be tested in 25 medical centers across the country among 26 thousand volunteers. Test takers are paid travel and other required benefits.
The Covaxin vaccine was approved after the successful completion of the first two phases of trials, which involved about 800 people.
Rector Mansur Twitter urged citizens to volunteer to register to participate in “groundbreaking research to develop better treatments and treatments.”
Volunteered myself for Phase III trial of COVID19 vaccine “Covaxin”- a study led by AMU in collaboration with ICMR & Bharat Biotech aimed at evaluating the safety and efficacy of this vaccine. (1/2) https://t.co/p8aQavveoG
— Tariq Mansoor (@ProfTariqManso1) November 10, 2020
Two more vaccines are currently being tested in India: Covishield (developed by Oxford University and the British-Swedish company AstraZeneca) and ZyCoV-D (developed by the Indian pharmaceutical company Zydus Cadila).
